TLR2 and myelodysplastic syndrome: TLR2 agonists induce the expression of IL‐1β in dendritic cells in the BM, in addition to having an impact on the functions of HSCs, activating them and promoting expansion and mobilization. Manipulation of the TLR2 pathway may improve HSC function in MDS [25]